BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16892896)

  • 21. [Primary myelodysplastic syndrome in children].
    Kuzmanović M; Bunjevacki G; Rasović N; Vujić D; Mićić D; Guć-Sćekić M; Jovanović V
    Srp Arh Celok Lek; 2001; 129 Suppl 1():10-6. PubMed ID: 15637984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The myelodysplastic syndrome and autoimmunity].
    Laursen SB; Nielsen MØ; Hasselbalch HC
    Ugeskr Laeger; 2009 Sep; 171(37):2639-42. PubMed ID: 19758507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
    Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
    Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS).
    Cantù Rajnoldi A; Fenu S; Kerndrup G; van Wering ER; Niemeyer CM; Baumann I;
    Ann Hematol; 2005 Jul; 84(7):429-33. PubMed ID: 15838669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes.
    Bacher U; Haferlach T; Kern W; Weiss T; Schnittger S; Haferlach C
    Cancer; 2009 Oct; 115(19):4524-32. PubMed ID: 19569249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers.
    De Roos AJ; Deeg HJ; Davis S
    Cancer Causes Control; 2007 Dec; 18(10):1199-208. PubMed ID: 17823848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
    Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical relevance of cytogenetics in myelodysplastic syndromes.
    Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Dambruoso I; Caresana M
    Ann N Y Acad Sci; 2006 Nov; 1089():395-410. PubMed ID: 17261783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic stem cell transplantation for myelodysplastic syndrome.
    Barrett AJ; Savani BN
    Semin Hematol; 2008 Jan; 45(1):49-59. PubMed ID: 18179969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.
    Oliansky DM; Antin JH; Bennett JM; Deeg HJ; Engelhardt C; Heptinstall KV; de Lima M; Gore SD; Potts RG; Silverman LR; Jones RB; McCarthy PL; Hahn T
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):137-72. PubMed ID: 19167676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact on survival of different treatments for myelodysplastic syndromes (MDS).
    Nachtkamp K; Kündgen A; Strupp C; Giagounidis A; Kobbe G; Gattermann N; Haas R; Germing U
    Leuk Res; 2009 Aug; 33(8):1024-8. PubMed ID: 19185917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myelodysplastic syndromes in the adolescent.
    Winter SS; Mathew P; Vaughan RL; Foucar K
    Adolesc Med; 1999 Oct; 10(3):401-6, x. PubMed ID: 10611937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
    Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
    Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia.
    Hui CH; Horvath N; Lewis I; To LB; Szabo F
    Intern Med J; 2008 Nov; 38(11):824-8. PubMed ID: 18284457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myelodysplastic syndrome associated with monosomy 7 in childhood: a retrospective study.
    Aktas D; Tuncbilek E
    Cancer Genet Cytogenet; 2006 Nov; 171(1):72-5. PubMed ID: 17074595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous stem cell transplantation in myelodysplastic syndromes.
    de Witte T; Suciu S; Brand R; Muus P; Kröger N
    Semin Hematol; 2007 Oct; 44(4):274-7. PubMed ID: 17961727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
    Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
    Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A practical, comprehensive classification for pediatric myelodysplastic syndromes: the CCC system.
    Mandel K; Dror Y; Poon A; Freedman MH
    J Pediatr Hematol Oncol; 2002; 24(5):343-52. PubMed ID: 12142781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
    Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S
    Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.